Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metformin/sitagliptin - Merck & Co

Next Previous
X
Search
Drug Profile

Metformin/sitagliptin - Merck & Co

Alternative Names: Efficib; Januet; Janumet; Metformin hydrochloride mixture with sitagliptin phosphate; MK-0431A; ONO 5434A; ONO-5435A; Ristfor; Sitagliptin/metformin; Velmetia

Latest Information Update: 06 May 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Class Antihyperglycaemics; Biguanides; Fluorobenzenes; Insulin sensitisers; Ketones; Pyrazines; Small molecules; Triazoles
  • Mechanism of Action AMP activated protein kinase stimulants; Dipeptidyl peptidase 4 inhibitors; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 16 Apr 2021 Metformin/sitagliptin is still in phase III trial for Type 2 diabetes mellitus (In adolescents, In children) in Latvia, Lithuania, Italy, Germany, United Kingdom, Romania, Mexico, Canada, Argentina, Chile, Colombia, Costa Rica, Dominican Republic, Guatemala, Israel, Malaysia, Thailand, New Zealand, Russia, United Arab Emirates, Sri Lanka, Saudi Arabia and Bulgaria (NCT01472367) (EudraCT2011-002529-23)
  • 17 Sep 2019 Merck Sharp & Dohme Corp completes a phase III trial in Type 2 diabetes mellitus (In adolescents, In children) in Latvia, Lithuania, Italy, Germany, United Kingdom, Romania, Mexico, Canada, Argentina, Chile, Colombia, Costa Rica, Dominican Republic, Guatemala, Israel, Malaysia, Thailand, New Zealand, Russia, United Arab Emirates, Sri Lanka, Saudi Arabia and Bulgaria(NCT01472367) (EudraCT2011-002529-23)
  • 15 Aug 2018 Depomed is now called Assertio Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top